TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06635850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosliciguat
Description: Dose level 1, 2, or 3 for inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosliciguat
Description: Dose level 1, 2, or 3 for inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery
Study: NCT05613881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Telephone Follow-up
Description: The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
Study: NCT06635850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery
Study: NCT06281938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight estimation using 3D camera
Description: Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care weight estimation
Description: Standard care (unspecified) will be used to determine weight-based dosing and other management.
Study: NCT05906173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Description: AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study: NCT05934942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin®
Description: Ethinylestradiol (EE) and Drospirenone (DRSP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study: NCT04979923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Study: NCT05341856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isosorbide mononitrate
Description: insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
Study: NCT05928182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: El Faro Treatment Intervention
Description: Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\].
Study: NCT05341856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
Study: NCT06080698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Antibiotics
Description: Participants will continue to receive intravenous antibiotics until the completion of the treatment course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antibiotics
Description: Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
Study: NCT06022822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urolithin A Supplement
Description: Given PO
Study: NCT06512194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Psilocybin
Description: The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.
Study: NCT06276296

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter EKG - 1 day before ablation
Description: 24 hours Holter EKG - 1 day before ablation

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter EKG - 1 day before ablation
Description: 24 hours Holter EKG - 1 day before ablation

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Pulmonary vein isolation using radiofrequency ablation

Intervention type: PROCEDURE
Intervention: Pulsed field ablation
Description: Pulmonary vein isolation using pulsed field ablation

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter EKG - 1 month after ablation
Description: 24 hours Holter EKG 1 month after ablation

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter EKG - 1 month after ablation
Description: 24 hours Holter EKG 1 month after ablation
Study: NCT06361550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VENREDI group
Description: Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
Study: NCT06635850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for inhalation
Study: NCT06361550

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education on Mediterranean diet
Study: NCT04834336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training device
Description: Inspiratory muscle training will be performed with an inspiratory muscle training device.
Study: NCT05154916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Relaxation Program
Description: Virtual Reality Based Relaxation Program
Study: NCT06429410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified formula milk powder
Description: Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
Study: NCT04834336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
Study: NCT06628960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Su Jok Therapy
Description: Su Jok Therapy
Study: NCT06213298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kava
Description: 75 mg kavalactones
Study: NCT06429410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula milk powder
Description: Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: regular milk powder
Description: Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
Study: NCT05198635

Intervention type: DEVICE
Intervention: local cerebral oxygen saturation
Description: minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold

Intervention type: DEVICE
Intervention: local cerebral oxygen saturation
Description: minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
Study: NCT06213298

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT05211466

Intervention type: OTHER
Intervention: Digital healthcare platform
Description: In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.

Intervention type: OTHER
Intervention: Digital healthcare platform
Description: In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.

Intervention type: OTHER
Intervention: Digital healthcare platform
Description: In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.

Intervention type: OTHER
Intervention: Digital healthcare platform
Description: In this specific digital healthcare platform, patients can enter symptoms and get an initial digital triage by artificial intelligence (AI). After the artificial intelligence (AI) has assessed the symptoms, the patient can be triaged to digital healthcare advices, or a chat with a healthcare professional. If needed, the healthcare professional can convert the chat to a telephone or video assessment, or book the patient to a healthcare specialist. The platform can also administer planned consultations with patients or between professionals, it can be used as a tool for the patient to book healthcare appointments, get diagnostics and assessments done, and receive treatment through.
Study: NCT05968937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg baclofen vaginal suppository daily per vagina
Description: 20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal suppository composed of Supposibase F daily per vagina
Study: NCT05129735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacement shake
Description: Each day for the study period (12 weeks), the participants will take one meal-replacement shake per day for breakfast. The breakfast will be replaced by the shake entirely.
Study: NCT04660682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified static cross-body posterior shoulder stretching
Description: For the modified cross-body position patient will be positioned in the side-lying position to limit the scapular abduction, and the patient aligned his/her forearms to limit the ER of the humerus while moving into horizontal adduction (HAdd). First, we will ask the patient to pull his/her arm into HAdd to the physiological barrier of the ROM, and then the patient will perform active-assistive static stretching with the help of the other hand for 30 seconds. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional static cross-body posterior shoulder stretching
Description: For the traditional static cross-body posterior shoulder stretching, in the standing position, the patient will perform cross-body stretch alone by active-assistive pulling the humerus across the body into HAdd with the opposite arm, without concern for scapular stabilization for 30 sec. The stretching will perform five repetitions with 10-sec rest between stretches. Each stretching will begin from a new physiological barrier of the HAdd ROM. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: In sham stretching, the patient will be positioned in the traditional static cross body posterior shoulder stretching position, and then the patient will perform active-assistive HAdd ROM without enough stretching of the relevant tissue. Active assistive ROM will be stopped before reaching the individual PST measurement result (in this way, sham stretching will be performed without proper stretching of the relevant tissue). The HAdd ROM exercise will be performed 5 times. Patients will also receive the standard physiotherapy program consists of physical agents, posture, proprioceptive, and strengthening exercises. The treatment program will be performed 5 days a week under the physiotherapist's supervision and 2 days a week as a home program for 8 weeks.
Study: NCT04128371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mepolizumab
Description: Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials were reconstituted according to the manufacturer, for a total dose of 700mg administered as intravenous infusion.
Study: NCT06348680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video assisted episiotomy repair training
Description: Midwifery Intervention The 'video recording' prepared by researchers specialized in the field of midwifery to increase the episiotomy repair skills of midwifery students will be used as training material. The content of the video recording is as follows: control before episiotomy repair, episiotomy repair, subcutaneous suturing, skin suturing, suturing techniques (Continuous, Simple Intermittent, Mattress). After the video recording is completed, it will be restarted and shown to the students in the experimental group continuously throughout the application period. At the end of the application period, students will be re-evaluated.
Study: NCT05126680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy: intermittent treadmill walking exercise and moderate intensity functional training
Description: Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (15-30 min.) and moderate intensity functional training (MIFT) (15 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min. In MIFT, subjects must complete in 15 min. the highest number of repetitions / rounds possible (AMRAP) to a circuit composed of 6 global functional exercises from which they performed 10 repetitions with a rating of perceived exertion (RPE) of 5-7 on a 1 to 10 scale in each exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise therapy: intermittent treadmill walking exercise
Description: Subjects will perform a 12-week supervised exercise therapy program based on intermittent treadmill walking exercise (30-45 min.). In intermittent treadmill walking exercise, the speed and incline of treadmill will be adjusted that patients achieve moderate claudication pain in the time interval between 3 and 5 min.
Study: NCT05405413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment recommendations made by Molecular Tumor Board.
Description: Molecular Tumor Board recommendations may include any of the following:~(A) a tumor-targeted drug (alone or in combination)~(B) an antibody-based immunotherapy (alone or in combination)~(C) neither (A) nor (B).~(D) referral to the Familial Cancer Program~(E) referral for germline genetic testing
Study: NCT05800873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVER001
Description: A highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases.
Study: NCT05738629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops
Description: Participants will receive artificial tears for 2 weeks to get the normalized baseline, followed by PSC-MSC-Exo eye drops 0.125 ml/single eye/one time, four times a day for 12 weeks. The follow-up visit will be 12 weeks since the administration of PSC-MSC-Exo eye drops.
Study: NCT06512194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The psilocybin is produced under Good Manufacturing Practice and is in a capsule that contains 25 mg of synthetic psilocybin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
Study: NCT05426798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection azacitidine, AZA decitabine, DAC
Description: Drug1: TQB2618 injection is a novel tim-3 inhibitor.~Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter hypomethylation.~Drug3: Decitabine is a cytidine deoxy nucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
Study: NCT05713838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg Durvalumab, IV, day 1 Q4W (max. 15 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT
Description: 50 mg/m² docetaxel, 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate and 2600 mg/m² fluorouracil as 24 h-infusion, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX-6
Description: 85 mg/m² oxaliplatin, 200 mg/m² calcium folinate, 400 mg/m² fluorouracil as bolus dose and 1600 mg/m² fluorouracil as 48 h-infusion, ² cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 5 weeks with 5 days a week radiotherapy (25 daily fractions with 2.0 Gy = ∑50Gy)
Study: NCT05152485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIB104 Reference Formulation
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104 Test Formulation
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB104 Test Formulation
Description: Administered as specified in the treatment arm
Study: NCT06512194

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham taVNS
Description: For both the active and sham taVNS procedure, participants will be provided with, and trained on, use of a taVNS device that applies gentle stimulation to the left ear.
Study: NCT04794088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate intravenous solution
Description: A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 200mg imatinib (100mg/h).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 25ml volume of IMP will be administered over 2-hours as an intravenous infusion. This corresponds to a dose of 25ml placebo (12.5ml/h).
Study: NCT06512194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as usual consists of an integration 1-day, 1-week, and 2-weeks post-psilocybin dosing.
Study: NCT05610514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-Cigarette
Description: Altering the availability of e-cigarettes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Altering the availability of financial incentives for abstaining from combustible cigarettes
Study: NCT06359990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrotherlyACT
Description: BrotherlyACT is a digital intervention to prevent youth violence and substance use among trauma-exposed young Black males, ages 125-24. This intervention combines life skills coaching, safety planning tools, and an AI-driven chatbot to reduce the risk and effects of violence and early substance use.

Intervention type: OTHER
Group type: OTHER
Intervention: BrotherlyACT Waitlist Control Group (WCG)
Description: During the waiting period, participants in the control group do not receive the BrotherlyACT intervention but may continue with their usual activities or interventions.